Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis
Publication Type:
Journal Article
Authors:
Asselah, Tarik;
Kowdley, Kris V.;
Zadeikis, Neddie;
Wang, Stanley;
Hassanein, Tarek;
Horsmans, Yves;
Colombo, Massimo;
Calinas, Filipe;
Aguilar, Humberto;
de Lédinghen, Victor;
Mantry, Parvez S.;
Hezode, Christophe;
Marinho, Rui Tato;
Agarwal, Kosh;
Nevens, Frederik;
Elkhashab, Magdy;
Kort, Jens;
Liu, Ran;
Ng, Teresa I.;
Krishnan, Preethi;
Lin, Chih-Wei;
Mensa, Federico J.Source:
Clin Gastroenterol Hepatol, Volume 16, Issue 3, p.417-426 (2018)
Keywords:
DAA,
Direct-Acting Antiviral,
Pangenotypic,
Short-duration
